Serotonin is important in brain functions and involved in neurological diseases. It is also drawn considerable attention in bone disease since it mainly produced by the gut. Serotonin 6 G-proteincoupled receptor (5-HT 6 R) is clinical targets for the treatment of neurological diseases. However, 5-HT 6 R as a therapeutic target in bone has not been reported. Herein, we found that 5-HT 6 R showed higher expression in bone, and its expression was increased during bone remodeling and osteoblast differentiation. The activation of 5-HT 6 R by ST1936 caused the inhibition of ALP activity and mineralization in primary osteoblast cultures, which was antagonized by SB258585, an antagonist and by the knockdown of 5-HT 6 R. Further investigation indicated that 5-HT 6 R inhibited osteoblast differentiation via Jab1 in BMP2 signaling but not PKA and ERK1/2. In vivo studies showed that the activation of 5-HT 6 R inhibited bone regeneration in the calvarial defect mice and also delayed bone development in newborn mice; this response was antagonized by SB258585. Therefore, our findings indicate a key role of 5-HT 6 R in bone formation through serotonin originating in the peripheral system, and suggest that it is a novel therapeutic target for drug development in the bone repair and bone diseases.
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. However, most serotonin is found outside of the central nervous system and is mainly synthesized in the gut by tryptophan hydroxylase-1 (Tph-1) 2 . 95% of total body serotonin is released into the gut by enterochromaffin cells and enter into blood circulation, indicating that the serotonin system has various functions beyond actions of serotonin as a well-known neurotransmitter 3, 4 . The recent research was reported that a serotonin-mediated system originating in the gut can regulate bone mass 5, 6 . Selective serotonin reuptake inhibitors (SSRIs) reduced bone mass in mice 7 and also clinical data showed a significant increase for fractures in patients treated with SSRIs 8 . Yadav et al. found that serotonin production in the gut can enter into blood circulation and reduce bone formation 5 . Reporting in Nature medicine, Yadav et al. also reported that pharmacological inhibition of gut-derived serotonin synthesis by LP533401, a small molecule inhibitor of Tph-1 is a potential therapeutic treatment for low-bone-mass diseases 9 . The physiological diversity of serotonin system is mediated by multiple serotonin receptors (5-HTRs), which have been divided into seven classes (5-HT 1 R through 5-HT 7 R) on the basis of their signaling pathway 10 . Among them, 5-HT 6 R, a G-protein-coupled receptor (GPCR) is one of the latest cloned receptor and positively coupled to adenylyl cyclase via stimulatory G (Gs) proteins and increases intracellular cyclic AMP (cAMP) production by Scientific RepoRts | 6:30985 | DOI: 10.1038/srep30985 the activation of adenylyl cyclase 11 . It was previously demonstrated that 5-HT 6 R physically and functionally interacts with various proteins including Fyn tyrosine kinase and Jun activation domain-binding protein 1 (Jab1) 12, 13 . Over the past decades, the 5-HT 6 R has gained increasing attention in the brain and has become a clinical target for treating neurological diseases such as Alzheimer's diseases, depression, and schizophrenia [14] [15] [16] . However, there is no study for 5-HT 6 R in the peripheral organs.
In the present study, we investigated the relative expression of 5-HT 6 R in bone compared to brain, and examined its role in in vitro osteoblast differentiation and in vivo bone regeneration and bone development via peripheral serotonin system. Our findings indicate that 5-HT 6 R has a crucial role in bone metabolism and will shed light on how peripheral serotonin system regulates bone metabolism.
Results and Discussion
In an effort to elucidate how peripheral serotonin system regulates bone formation, we first examined the relative expression of repective 5-HTRs between the bone and brain. Our results showed that 5-HT 6 R showed relatively higher expression in bone compared to brain (Fig. 1A) . Given that 5-HT 6 R has been gaining great attention for treating neurological diseases in brain 14, 17, 18 , it is very important to elucidate the fundamental mechanisms responsible for peripheral serotonin-mediated bone formation via 5-HT 6 R.
Following critical-sized calvarial bone defects, the expression level of 5-HT 6 R increased in the early stage of differentiation or remodeling (Fig. 1B) and also the 5-HT 6 R mRNA level was upregulated in a time-dependent manner and followed by a decrease (Fig. 1C,D) , suggesting that 5-HT 6 R might have regulatory or tuning roles to prevent abnormal osteoblast differentiation.
Primary osteoblast cultures from newborn mouse calvaria are capable of differentiating in vitro into mature osteoblasts that is characterized by increased expression of the early marker alkaline phosphatase (ALP), later marker osteocalcin (OCN), and mineralization 19 . To examine the role of 5-HT 6 R in osteoblast differentiation and function in vitro, primary osteoblasts were cultured and treated with a recently developed selective 5-HT 6 R agonist, ST1936 20 . The activation effects of 5-HT 6 R were determined by ALP activity and the formation of mineralized bone nodules. ALP staining (Fig. 1E) and mineralization (Fig. 1F ,G) were decreased with ST1936 treatment in a concentration-dependent manner. The effects of 5-HT 6 R was antagonized by SB258585, a specific antagonist (Fig. 1H) and attenuated by the knockdown of endogenous 5-HT 6 R (Fig. 1I) , indicating that 5-HT 6 R is involved in osteoblast differentiation for serotonin-mediated bone formation.
The bone morphogenetic protein-2 (BMP-2) signaling pathway plays an important role in osteoblast differentiation and subsequent bone formation or remodeling 21 . Canonical BMP-2 signaling occurs through the phosphorylation of Smad1/5/8 and induces subsequent activation of the transcription of bone-specific genes, leading to bone formation 22 . To determine the mechanism underlying the effect of 5-HT 6 R in osteoblast differentiation, the effect of 5-HT 6 R on BMP-2 signaling was examined in primary calvarial osteoblasts. Our data demonstrated that the treatment with ST1936 attenuated the phosphorylation of Smad1/5/8, the central molecules in BMP-2 signaling ( Fig. 2A) , and decreased the expression of Runx2, the downstream target gene of BMP-2 signaling (Fig. 2B ). To further understand the role of 5-HT 6 R in osteogenic differentiation, rh-BMP-2 was treated with ST1936 in primary calvarial osteoblasts. Rh-BMP-2-induced ALP activity and mineralized nodule formation in primary osteoblasts were suppressed dramatically by ST1936 ( Fig. 2C-F) . Thus, these results suggested that the BMP-2 signaling pathway has an important role in 5-HT 6 R-mediated differentiation and function of osteoblasts.
5-HT 6 R is a GPCR that increases cAMP by stimulating adenylyl cyclase, leading to the activation of PKA 18 . These GPCRs typically act through Gs proteins in response to extracellular stimuli including growth factors and neurotransmitters 23 . We firstly reported the cellular mechanisms of 5-HT 6 R-mediated Gs protein signaling via Ras-Raf-MEK-ERK1/2 pathway, providing new insights into the physiological roles of 5-HT 6 R in brain 12, 13, 24 . However, we, herein, observed that the differentiation of primary osteoblasts is not related to the Gs protein signaling of 5-HT 6 R (the PKA and ERK1/2 pathway) ( Fig. 2G-J ). Similar to our observation, reporting in Nature Chem Biol, Seo et al. 23 , and Duhr et al. 25 , also described that 5-HT 6 R controls neuronal differentiation through the CDK5 pathway in a Gs protein-independent signaling.
It was previously reported that 5-HT 6 R physically and functionally interacts with Jab1 and the activation of 5-HT 6 R releases Jab1 13, 24 . Jab1 has been reported to interact with Smad5 and cause an attenuation of BMP-dependent transcriptional responses, suggesting that Jab1 might act as an inhibitor of BMP signaling 26 . Also, Chen et al., reported that knockout of Jab1 increased BMP-induced phosphorylation of Smad1/5 compared with wild-type controls, but not TGF-beta induced Smad2/3 27 . We, therefore, examined whether 5-HT 6 R modulates BMP2 signaling via Jab1 in primary osteoblasts. In the present study, the knockdown of endogenous Jab1 by RNA interference significantly enhanced rh-BMP-2-induced phosphorylation of Smad1/5/8, in a time-dependent manner (Fig. 3A,B) , and the activation of 5-HT 6 R stimulated the binding of Jab1 with Smad1/5/8 (Fig. 3C) . Moreover, the knockdown of Jab1 attenuated 5-HT 6 R agonist induced-Runx2 suppression (Fig. D) as well as osteoblast differentiation as evidenced by ALP staining (Fig. 3E ) and activity (F) and differentiation markers, ALP, OCN, and bone sialoprotein (BSP) (Fig. 3G-I ). These data suggest that 5-HT 6 R inhibits bone formation via Jab1-mediated BMP2 signaling.
The hypothesis that 5-HT 6 R inhibits bone formation via peripheral serotonin-mediated system was supported by the osteogenic effect of 5-HT 6 R in in vivo animal experiments (Fig. 4) . To that end, we generated mice with surgery-generated calvarial defect, and bioabsorbable collagen sponge loaded with ST1936 (10 mg/kg) was placed into the defects (Fig. 4A) . The local delivery of ST1936 into critical-sized mouse calvarial defects elicited an impaired osteogenic response (Fig. 4B-D) . New bone formation visualized by 3D micro-CT images (μCT) was particularly decreased in defects treated with ST1936 (Fig. 4B ) and the amount of new bone formation in the ST1936-treated group was significantly lower than that in the control group (P < 0.05) (Fig. 4C) . Histological evaluation further supported the μCT findings, showing newly formed bone within the defect in controls, and no bone formation in the ST1936-treated group (Fig. 4D) , indicating that 5-HT 6 R is required for osteoblast bone formation.
Calvarial sutures are major growth sites of intramembranous osteogenesis during craniofacial bone development 28, 29 ; thus, we further investigated whether 5-HT 6 R signaling has a critical role in intramembranous osteogenesis of calvarial bone and suture development. ST1936 or SB258585 was treated for the indicated embryonic period, and the phenotypes of bone in mice were analyzed (Fig. 4E-G) . Sequential staining of mice skeletons revealed an increase in the ratio of cartilaginous (blue) to mineralized tissue (red) in the ST1936-adminstrated calvarial bones such as two frontal, two parietal, and an interparietal bone, whereas SB258585 administration reversed the effects of ST1936 (Fig. 4H) . Such deformities of bones are mainly observed in calvarial sutures that are main centers for osteoblast differentiation and new bone formation postnatally 29 . We next examined osteoblast differentiation in calvarial bones by measuring the earliest molecular determinant of bone formation (Runx2) and late osteoblast differentiation markers (OCN and BSP) 30 . Our results showed that the 5-HT 6 R antagonist significantly reversed the 5-HT 6 R agonist-suppressed expression of Runx2 (Fig. 4I) and osteoblast-related genes, OCN and BSP (Fig. 4J,K) . Taken together, these in vivo results demonstrated that 5-HT 6 R is a critical receptor to regulate bone formation in peripheral serotonin-mediated system.
In conclusion, these experiments have uncovered a novel link between peripheral serotonin system and 5-HT 6 R in bone formation. This is the first study to demonstrate that 5-HT 6 R is expressed in bone, which is crucial for in vitro osteoblast differentiation and in vivo bone development and regeneration in animal models via peripheral serotonin-mediated system. These findings suggest that 5-HT 6 R is a potential therapeutic target for bone repair and bone diseases, and will provide basic understanding on how peripheral serotonin-mediated system regulates bone formation.
Materials and Methods
Primary calvarial osteoblasts culture, differentiation, and transfection. Primary calvarial osteoblasts were isolated from calvariae of 1-day-old ICR mice using 0.2% collagenase-dispase enzyme solution (Sigma-Aldrich, St. Louis, MO). The cells isolated from the last four to six digests were cultured separately in α-modified minimum essential medium (α-MEM) (Gibco Laboratories, Grand Island, NY) containing 10% fetal bovine serum (FBS; Gibco Laboratories) and antibiotics (100 mg/mL penicillin G and 100 IU/mL streptomycin). After reaching a subconfluent state, the cells were removed from each flask and combined together as osteoblasts. The cells were used for all experiments at second passage, as described below. Cells were cultured in α-MEM containing 10% FBS, 5 mmol/L β-glycerophosphate, ascorbic acid (50 μg/mL), and antibiotics. For siRNA transfection, cells were transfected using Lipofectamine RNAiMAX according to the manufacturer's specification (Invitrogen, Carlsbad, CA, USA).
Mice and ethics statement. Female 8-week-old ICR mice (Samtako, Osan, Kyoung Gi-Do, Korea) used in this study were maintained in accordance with the National Institute of Toxicological Research of the Korea Food and Drug Administration guidelines for the humane care and use of laboratory animals. All experimental procedures in the current study were approved by Kyung Hee University Animal Care Committee (approval number: KHMC-IACUC 2015-002). All experimental methods were conducted in accordance with relevant guidelines.
Calvarial bone defects. The mice were anesthetized, and a 5-mm-diameter calvarial critical-sized defect was created on each side of the calvarial bone using a dental bur attached to a slow-speed hand piece with minimal invasion of the Dura mater. The wound was closed with CollaTape (Integra LifeSciences Corporation, Carlsbad, CA) containing ST1936 (10 mg/kg, Tocris Bioscience, Bristol, United Kingdom). Animals were sacrificed 8 weeks postsurgery and the calvarial bone was carefully excised, cleaned, and fixed immediately in 10% formalin. After imaging by micro-computerized tomography (μCT), tissues were demineralized in10% EDTA for 14 days, embedded in paraffin, and sectioned at 5 μm. Sections were stained with hematoxylin and eosin (H&E).
Micro-computed tomography (μCT). μCT was performed at the Advanced Institutes of Convergence
Technology (Genoss Co., Ltd., Gyeonggi-do Korea). Micro-CT data of calvaria were acquired on a Skyscan 1173 scanner (Bruker-microCT, Kontich, Belgium). Scanning was carried out at 75 kV/106 μA for 500 ms. In total, 800 projections were collected at a resolution of 9.94 μm/pixel. Reconstruction of sections was carried out with software associated with the scanner (Nrecon), with the beam hardening correction set to 40%. Realistic 3D-Visulizatio software (Bruker-microCT, Konitch, Belgium) was used to reconstruct the CT images three-dimensionally, which were acquired on approximately 2,000 cross-sections.
Calvarial bone development and skeletal staining. ALP activity. ALP activity was measured by spectrophotometry. Cells were homogenized in 0.5 mL of distilled water using a sonicator, and centrifuged. Aliquots of cell homogenate were incubated with 15 mm p-NPP in 0.1 m glycine-NaOH (pH 10.3) at 37 °C for 30 min. The reaction was stopped by the addition of 0.25 n NaOH. The absorbance was measured at 405 nm using an ELISA reader (Beckman Coulter).
ALP staining. Cells were washed with 1× PBS and then fixed in 4% formaldehyde for 20 min at room temperature. The cells were rinsed with distilled water, and permeabilized with 0.1% Triton X-100. Cells were incubated at 37 °C for 30 min in Naphthol-AS-BL alkaline solution mixture (Sigma-Aldrich).
Alizarin Red S staining. After 14 days of culture, cells were fixed in 70% ice-cold ethanol for 1 h and rinsed with distilled water. Cells were stained with 40 mM Alizarin Red S (pH 4.2) for 10 min with gentle agitation. The level of Alizarin Red S staining was observed under light microscopy. To quantify Alizarin Red staining, stains were eluted with 100% DMSO and measured at 590 nm.
Reverse transcriptase-polymerase chain reaction (RT-PCR) and quantitative real-time PCR.
The total RNA of cells was extracted using TRIzol ™ reagent (Life Technologies, Gaithersburg, MD) according to the manufacturer's instructions. RNA (1 μg) isolated from each sample was reverse-transcribed using oligo (dT) 15 primers with AccuPower ® RT PreMix (iNtRON Biotechnology, Gyeonggi-do, South Korea). Next, the generated cDNAs were amplified with AccuPower ® PCR PreMix For mRNA quantification, total RNA was extracted using the RNAqueous ® kit and the cDNA was synthesized using 1 μg of total RNA with the High Capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. Quantitative real-time PCR was performed using a LightCycler ® 1.5 System (Roche Diagnostics GmbH, Mannheim, Germany). Thermocycling conditions consisted of an initial denaturation of 10 s at 95 °C, followed by 45 cycles of 95 °C for 10 s, 60 °C for 5 s and 72 °C for 10 s. For the calculation of relative quantification, the 2 −ΔΔCT formula was used, where -ΔΔCT = (C T,target − C T,β-actin ) experimental sample -(C T,target − C T,β-actin ) control sample.
Western blot analysis. Cells were washed twice with ice-cold PBS, and lysed in 20 mM Tris-HCl buffer (pH 7.4) containing a protease inhibitor mixture (0.1 mM PMSF, 5 mg/mL aprotinin, 5 mg/mL pepstatin A, and 1 mg/mL chymostatin). Protein concentration was determined using Bradford reagent (Bio-Rad, Hercules, CA). Equal amounts of lysates (20 μg) resolved by sodium dodecyl-polyacrylamide gel electrophoresis (SDS-PAGE) were transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA), and the membrane was blocked with 1× TBS containing 0.05% Tween 20 and 5% skim milk or 2% BSA for 1 h at room temperature. After blocking, the membranes were incubated overnight at 4 °C with the respective primary antibodies, as follows: p-ERK1/2 (1:2000, #9101S, Cell Signaling Technology, Beverly, MA), ERK1/2 (1:2000, #9102S, Cell Signaling), Runx2 (O1L7F) (1:1000, #12556S, Cell Signaling), Jab1 (1:2000, #6895, Cell Signaling), p-Smad1/5/8 (D5B10) (1:2000, #13820S, Cell Signaling), Smad1/5/8 (N-18) (1:1000, #sc-6031-R, Santa Cruz Biotechnology, Santa Cruz, CA), β-actin (C4) (1:1000, #sc-47778, Santa Cruz Biotechnology). The membranes were washed with 1× PBS and incubated with diluted horseradish peroxidase (HRP)-conjugated secondary antibodies (1:10,000, Jackson ImmunoResearch, West Grove, PA) for 1 h at room temperature. After three washes, the membranes were detected using an enhanced chemiluminescence (ECL) kit (Millipore, Bedford, MA).
Co-immunoprecipitation.
Cells and tissues were gently lysed with lysis buffer for 1 h on ice and then centrifuged at 15,000 g and 4 °C for 15 min, and the supernatant was collected. The soluble lysates were incubated with mouse anti-Jab1 antibody (#sc-13157, Santa Cruz Biotechnology) at 4 °C, and then with Protein A/G bead (Santa Cruz Biotechnology) and washed times. Immune complexes were eluted by boiling for 10 min at 95 °C in SDS sample buffer, followed by Western blot analysis with anti-Jab1 (1:1000, Cell Signaling), anti-Runx2 (1:1000; Cell Signaling Technology), or anti-Smad1/5/8 (1:1000; Santa Cruz Biotechnology) antibodies.
Statistical analysis. The data were analyzed using GraphPad Prism version 5 software (GraphPad Software, Inc., San Diego, CA). Data are presented as the means ± S.E.M. Statistical significance was evaluated using one-way analysis of variance (ANOVA) and the differences were assessed by the Dunnett's test. A value of P < 0.05 was considered to indicate statistical significance.
